Noam Danenberg, CEO
Noam was appointed as our CEO on April 2019, and before that has served as a director and as our Chairman since November 7, 2018. He served as our Chief Operating Officer from the closing of the Merger on November 15, 2017 until November 7, 2018 and as a strategic advisor since April 2015. Since 2000, he has provided private investment consulting services to numerous private and public companies through his company, N. Danenberg Holdings (2000) Ltd and served as a founder, director, investment advisor to a number of pharmaceutical and medically-related companies. He holds a BBA in Computer Science from the European University, Antwerp, Belgium and an MBA from Boston University Brussels Graduate Center.
Or Eisenberg, CFO
Formerly controller of the Katzir Fund Group and external controller/Chief Financial Officer of certain public companies listed on Tel Aviv Stock Exchange. Prior to that he was an accountant with a member firm of Ernst & Young Global. He holds a BA in Economics & Accounting (Haifa U.) and is a CPA in Israel.
Dr. Adam Foley-Comer, Medical Director
Experienced in development, regulatory strategy, and clinical trial planning and conduct, with leading international pharmaceutical companies. Graduated in Medicine from Manchester University, is a Fellow of the Royal College of Surgeons and earned his MSc from University College, London.